What Is a Medical Device Go-to-Market Strategy That Drives Commercial Success?

Bringing a medical device to market is one of the most complex commercial challenges in B2B. The global MedTech industry reached an estimated USD $668.2 billion in 2024 and is projected to grow to $694.7 billion by 2025, according to MarketsandMarkets MedTech Industry Outlook 2025. Yet growth at the market level does not translate to success at the product level. Most MedTech launches fail not because the device lacks clinical merit, but because the commercial strategy underestimates the complexity of the buying environment.

Medical device purchases involve clinicians, hospital administrators, procurement teams, payers, and patients who arrive as informed advocates for specific technologies. Each stakeholder evaluates value differently. The device that earns clinical enthusiasm but fails to address payer reimbursement pathways or procurement risk criteria will stall before it scales.

At Pace Creative, we have built go-to-market strategies for MedTech companies across diagnostics, surgical systems, and medical aesthetics including the Cutera Secret RF launch that generated Q2 sales targets in 6 weeks and 4x expected sales in Year 1. This post covers the components of a high-performance medical device go-to-market strategy in 2026, from regulatory timing through buyer education and commercial content. For the broader framework that connects product launches to revenue growth, see how data-driven product launch strategy applies across MedTech and beyond.

Why Do Most Medical Device Launches Fall Short of Commercial Expectations?

The answer is not regulatory failure. Most medical device companies navigate regulatory approval with reasonable competence. The commercial gap opens downstream, when a cleared device enters a market without the infrastructure to support adoption at scale.

McKinsey’s MedTech Pulse report identifies four commercial execution patterns that separate high performers from the rest: superior market access planning, buyer-segmented value communication, early key opinion leader development, and integrated sales and marketing alignment. Companies that execute all four consistently outperform their peers in first-year revenue and sustained market share.

The compounding challenge is that the buying committee for medical devices has expanded. Where procurement decisions once rested primarily with the clinical champion, hospital purchasing now involves value analysis committees, supply chain leads, biomedical engineers, finance directors, and C-suite approvers, each with different information needs and risk tolerances, according to Gartner B2B Buying Journey research. A launch strategy that does not create content and conversation for each of these stakeholders leaves deals incomplete.

“MedTech companies that combine superior commercial capabilities with digital engagement tools consistently outperform peers in first-year revenue. The differentiator is the go-to-market infrastructure built around it.”

Source: McKinsey: What to Expect from MedTech in 2024

What Are the Five Core Components of a Medical Device Go-to-Market Strategy?

Regulatory and Reimbursement Roadmap

Commercial planning must begin in parallel with regulatory preparation, not after clearance is obtained. The FDA’s 510(k) pathway, used for the majority of moderate-risk Class II devices, has a 90-day standard review target, but FDA performance data shows that the actual median total time from submission to decision extends significantly beyond that when additional information requests are included. High-risk Class III devices navigating the PMA pathway face a standard review period of 180 days or longer.

Every month of commercial delay after clearance is lost revenue. Companies that build their market access plan, payer strategy, distribution agreements, and commercial content before clearance arrives can activate the commercial engine within weeks rather than months of FDA decision. Reimbursement strategy such as securing CPT codes, understanding payer coverage policies, and documenting health economic evidence, belongs on the pre-launch timeline alongside clinical validation.

2. Stakeholder-Mapped Value Communication

The same device delivers different value to different stakeholders, and the commercial content must reflect that. Clinical users care about procedural outcomes, safety profile, learning curve, and patient experience. Hospital administrators care about reimbursement rates, capital budget requirements, and contract terms. Procurement and value analysis committees care about total cost of ownership, vendor reliability, and supply chain risk.

Deloitte’s MedTech commercial transformation research identifies that the companies moving fastest from product approval to commercial scale are those treating the transition from “product supplier” to “strategic health system partner” as a deliberate communications strategy. This means building content that demonstrates total value such as  clinical, operational, and financial, rather than product features alone.

3. Key Opinion Leader and Clinical Champion Development

In MedTech, peer credibility is the most powerful commercial force. A surgeon or clinician who has achieved excellent outcomes with a device and communicates those results at conferences, in case studies, or through peer-reviewed publications accelerates adoption far more effectively than any marketing campaign. KOL development is not a post-launch activity as it begins with design validation studies and early access programs that create advocates before the device is commercially available.

Digital channels have amplified the reach of clinical champions significantly. According to Deloitte’s digital strategy research for MedTech, companies that integrate digital tools with their clinical education programs, including virtual demonstrations, training portals, and evidence libraries, achieve higher adoption rates across geographies than those relying on in-person-only engagement.

4. Multi-Channel Buyer Education

Medical device buyers research independently before and between vendor interactions. Gartner research confirms that B2B buyers spend only 17% of their total purchase process in direct contact with suppliers. The rest is self-directed research through digital content, peer communities, and reference checks. For MedTech, this means your product website, clinical evidence library, case studies, and video demonstrations must be able to advance a buyer’s evaluation without a sales rep in the room.

Effective buyer education content for medical devices covers three distinct needs: clinical evidence and outcomes data for the procedure, economic and operational justification for the administrator, and implementation and support documentation for the technical evaluator. These three content streams should be available through an organized digital hub, indexed and findable through search.

On WordPress, Yoast SEO ensures that clinical evidence pages, product specifications, and case studies are technically structured for organic discovery,  including proper schema markup, meta descriptions, and content readability scoring. SEMrush keyword research identifies the specific clinical and commercial terms your target buyers are searching for, enabling the content plan to be built around actual search demand rather than internal assumptions about what buyers want to know.

5. Integrated Sales and Marketing Alignment

MedTech launches stall when the commercial team and the marketing function operate independently. Marketing generates awareness content that sales cannot use in clinical conversations. Sales identifies objections that marketing has not addressed in existing materials. Forrester’s research on commercial alignment consistently shows that organizations aligning sales, marketing, and medical affairs around shared commercial objectives achieve significantly faster time-to-revenue than siloed counterparts.

For medical devices, this alignment requires a shared content architecture: pre-call materials that prime buyers on clinical evidence, objection-handling guides built from actual sales conversation data, and case studies that reflect the exact challenges faced by target health systems.

See how content marketing and sales enablement applies directly to MedTech commercial environments.

“The MedTech companies advancing fastest from product supplier to health system partner are those making the transition through deliberate commercial capability-building not just product innovation. Digital engagement, value communication, and KOL strategy are the commercial differentiators of the next decade.”

Source: Deloitte: MedTech Industry Trends and Commercial Transformation

How Does Digital Content Drive Medical Device Commercial Success?

The MedTech industry has historically been slower than other B2B sectors to invest in digital content infrastructure. That lag is now a meaningful competitive disadvantage. Deloitte’s MedTech digital transformation research shows that companies moving from “doing digital”, applying digital capabilities ad hoc, to “being digital”, designing a differentiating digital strategy. Being digital are achieving faster adoption across geographies and faster time-to-value from commercial investments.

For medical device companies, the highest-impact digital content investments are:

• 3D product and procedure animations: Medical devices are often difficult to visualize from a specification sheet. High-quality 3D animation that demonstrates the device in use by showing the mechanism of action, anatomical context, procedural steps, and patient outcomes, is the single most effective way to educate physicians before an in-person demonstration. The Cutera Secret RF launch (below) demonstrates what this looks like in practice.
• Clinical evidence libraries: Organized, searchable collections of clinical studies, peer-reviewed publications, real-world evidence, and case outcomes give procurement and value analysis committees the documentation they need to build an internal business case. These libraries also improve organic search visibility when properly structured through Yoast and targeted with SEMrush keyword research.
• ROI and health economics calculators: Financial decision-makers need evidence of economic value, not just clinical outcomes. Interactive calculators that model cost per procedure, length-of-stay impact, reimbursement rate assumptions, and payback period translate clinical benefit into financial terms that hospital finance teams and C-suite approvers can act on.

See the Marketing ROI Calculator as an example of this content type in a marketing context.

• Video testimonials from clinical champions: A 2-3 minute video of a surgeon describing a specific patient outcome, with named procedure, named result, and specific clinical context, carries more commercial weight than any written case study. These assets are highly resistant to AI-generated substitution, which means their credibility advantage is increasing, not decreasing.

What Does a Successful MedTech Launch Look Like in Practice?

Pace Creative worked with Cutera, a global innovator in medical aesthetic practices, on the commercial launch of the Secret RF micro-needling system across North America. The challenge: how to demonstrate a sophisticated procedural device to physicians across a continent without the ability to conduct live demonstrations at scale, before the physical product was even available.

Pace Creative built a fully integrated launch strategy that centered on a photo-realistic 3D animation of the Secret RF system, showing mechanism of action, needle depth variability, temperature control, and patient tissue response in a clinically accurate format that served both physician education and patient communication needs simultaneously. The animation functioned as the core commercial asset across every channel: digital advertising, conference presentations, sales enablement, and the product website.

The result: Q2 sales targets were met in 6 weeks. Cutera achieved 4x expected Year 1 sales, with ongoing ROI sustained beyond the initial launch period. The success came not from the animation alone, but from an integrated strategy that aligned clinical communication, digital distribution, and sales activation around a single compelling proof-of-concept asset.

See the full Cutera product launch case study and explore how Pace Creative’s approach to healthcare marketing applies across medical devices, life sciences, and health technology companies.

Other success stories:

• Sysmex Inostics, a molecular diagnostics company, to develop a new HubSpot website development. This included an optimized site map, a refreshed look, and valuable content as part of a healthcare content marketing strategy.
• Makana Masks, a manufacturer of reusable masks, partnered with Pace Creative to develop a product launch toolkit. This comprehensive approach helped Makana Masks improve their online presence, attract customers, and generate leads.
• Qualisure, a molecular testing company, we developed a promotional toolkit to increase their visibility among doctors and drive growth. This included a promotional campaign roadmap, campaign development, landing pages, infographics, and email content with the goal drive awareness within institutions and private practices in the US.

How Does Medtech AI and Digital Health Change the Launch Environment in 2026?

The launch environment for medical devices in 2026 is being shaped by two structural shifts identified by Deloitte’s 2026 MedTech Outlook.

1. Portfolio re-construction is accelerating: MedTech companies are concentrating investment in high-growth, high-margin therapeutic areas such as cardiovascular, neuromodulation, digital health, while divesting non-core assets. This concentration means that individual product launches are carrying higher commercial expectations and receiving greater executive scrutiny.
2. AI is becoming a core component of device capability. According to GlobalData analysis cited in Medical Device Network, medical device companies’ spending on AI reached $2.4 billion in 2024 and is expected to reach $11.9 billion by 2029. For commercial teams, AI-enabled devices require additional launch investment in physician education, explaining how the AI component works, how its recommendations should be interpreted, and what the regulatory and clinical validation basis is.

These two shifts make the quality of the go-to-market strategy more consequential than ever. A device that enters a high-growth therapeutic area with weak commercial infrastructure will be outcompeted by a technically inferior device with superior clinical education, stronger payer positioning, and better integrated sales and marketing alignment. For context on how these trends connect to broader healthcare marketing strategy, see the life science marketing strategy guide and healthcare digital growth strategy.

Ready to Build a MedTech Go-to-Market Strategy That Drives First-Year Results?

A successful medical device commercial strategy requires more than a cleared device and a sales team. It requires integrated planning across regulatory timing, stakeholder-segmented content, digital buyer education, clinical champion development, and measurement infrastructure that connects launch activity to commercial outcomes.

Pace Creative brings decade-long B2B marketing expertise to MedTech commercial strategy, with specific experience in surgical systems, medical aesthetics, diagnostics, and life sciences. Explore Pace Creative’s healthcare industry expertise, review the Cutera product launch case study, and use the Impact Framework to connect your launch investment to measurable commercial milestones.

Download the B2B marketing eBook or contact the Pace Creative team to discuss your MedTech go-to-market strategy.